A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.
Also called NCT06777238
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 274 participants
- Sponsor
- Registry
-
NCT06777238
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06777238. Randomized; triple masking; primary purpose treatment. Start 2025-02-24 (actual); primary completion 2026-07-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
- Acronym
- Optimum 1
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- GZR18
- Intervention (Drug)
- Placebo
- Lead sponsor
- Gan & Lee Pharmaceuticals.
Record details
- Record id
cardio:ct-nct06777238- Content hash
e358ec6514504e05673757ad17dc6e6478f90a8e01bec9eed53e347a0504af25